309 related articles for article (PubMed ID: 20112253)
1. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma.
Pellegrino R; Calvisi DF; Ladu S; Ehemann V; Staniscia T; Evert M; Dombrowski F; Schirmacher P; Longerich T
Hepatology; 2010 Mar; 51(3):857-68. PubMed ID: 20112253
[TBL] [Abstract][Full Text] [Related]
2. Polo-like kinase 1 contributes to the tumorigenicity of BEL-7402 hepatoma cells via regulation of Survivin expression.
He Z; Wu J; Dang H; Lin H; Zheng H; Zhong D
Cancer Lett; 2011 Apr; 303(2):92-8. PubMed ID: 21330050
[TBL] [Abstract][Full Text] [Related]
3. Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues.
Winkles JA; Alberts GF
Oncogene; 2005 Jan; 24(2):260-6. PubMed ID: 15640841
[TBL] [Abstract][Full Text] [Related]
4. Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma.
Wang XQ; Zhu YQ; Lui KS; Cai Q; Lu P; Poon RT
Clin Cancer Res; 2008 Nov; 14(21):6813-20. PubMed ID: 18980975
[TBL] [Abstract][Full Text] [Related]
5. Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53.
Calvisi DF; Simile MM; Ladu S; Frau M; Evert M; Tomasi ML; Demartis MI; Daino L; Seddaiu MA; Brozzetti S; Feo F; Pascale RM
Hepatology; 2011 Apr; 53(4):1226-36. PubMed ID: 21480327
[TBL] [Abstract][Full Text] [Related]
6. Polo-like kinases and oncogenesis.
Eckerdt F; Yuan J; Strebhardt K
Oncogene; 2005 Jan; 24(2):267-76. PubMed ID: 15640842
[TBL] [Abstract][Full Text] [Related]
7. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
8. Inhibition mechanism of a newly cloned candidate tumor suppressor gene JST during hepatocarcinogenesis and its abnormal expression in human hepatocellular carcinoma from Qidong liver cancer risk area, China.
Dong-Dong L; Xi-Ran Z
Hepatogastroenterology; 2004; 51(56):515-25. PubMed ID: 15086194
[TBL] [Abstract][Full Text] [Related]
9. Polo-like kinase 1 inhibition suppresses hepatitis B virus X protein-induced transformation in an in vitro model of liver cancer progression.
Studach LL; Rakotomalala L; Wang WH; Hullinger RL; Cairo S; Buendia MA; Andrisani OM
Hepatology; 2009 Aug; 50(2):414-23. PubMed ID: 19472310
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of Polo-like kinase 1 and baculoviral inhibitor of apoptosis repeat-containing 5 in TP53-mutated hepatocellular carcinoma.
Li Y; Zhao ZG; Luo Y; Cui H; Wang HY; Jia YF; Gao YT
World J Gastroenterol; 2020 Aug; 26(32):4786-4801. PubMed ID: 32921957
[TBL] [Abstract][Full Text] [Related]
11. Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression.
Petrelli A; Perra A; Schernhuber K; Cargnelutti M; Salvi A; Migliore C; Ghiso E; Benetti A; Barlati S; Ledda-Columbano GM; Portolani N; De Petro G; Columbano A; Giordano S
Oncogene; 2012 Oct; 31(42):4517-26. PubMed ID: 22249248
[TBL] [Abstract][Full Text] [Related]
12. [Expression and prognostic value of Polo-like kinase 1, E-cadherin in the patients with hepatocellular carcinoma].
Chen XJ; Wu LM; Xu XB; Feng XW; Xie HY; Zhang M; Shen Y; Wang WL; Liang TB; Zheng SS
Zhonghua Wai Ke Za Zhi; 2007 Oct; 45(19):1354-8. PubMed ID: 18241575
[TBL] [Abstract][Full Text] [Related]
13. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
Reagan-Shaw S; Ahmad N
FASEB J; 2005 Apr; 19(6):611-3. PubMed ID: 15661849
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas.
Jang YJ; Kim YS; Kim WH
Int J Oncol; 2006 Sep; 29(3):589-94. PubMed ID: 16865274
[TBL] [Abstract][Full Text] [Related]
15. Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma.
Kanaji S; Saito H; Tsujitani S; Matsumoto S; Tatebe S; Kondo A; Ozaki M; Ito H; Ikeguchi M
Oncology; 2006; 70(2):126-33. PubMed ID: 16645325
[TBL] [Abstract][Full Text] [Related]
16. RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation.
Bouhlal H; Ouled-Haddou H; Debuysscher V; Singh AR; Ossart C; Reignier A; Hocini H; Fouquet G; Al Baghami M; Eugenio MS; Nguyen-Khac E; Regimbeau JM; Marcq I
Oncotarget; 2016 Mar; 7(9):9832-43. PubMed ID: 26799423
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
Frau M; Feo F; Pascale RM
J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of the tumor suppressor Krüppel-like factor 6 (KLF6) by mutation or decreased expression in hepatocellular carcinomas.
Pan XC; Chen Z; Chen F; Chen XH; Jin HY; Xu XY
J Zhejiang Univ Sci B; 2006 Oct; 7(10):830-6. PubMed ID: 16972326
[TBL] [Abstract][Full Text] [Related]
19. In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain.
Bergeron M; Motter R; Tanaka P; Fauss D; Babcock M; Chiou SS; Nelson S; San Pablo F; Anderson JP
Neuroscience; 2014 Jan; 256():72-82. PubMed ID: 24128992
[TBL] [Abstract][Full Text] [Related]
20. Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells.
Tyagi S; Bhui K; Singh R; Singh M; Raisuddin S; Shukla Y
Biochem Pharmacol; 2010 Nov; 80(9):1326-34. PubMed ID: 20655883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
